Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 13/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KDM6B | O15054 | 1/20 | 0.34 |
| ▸ | KDM4A | O75164 | 1/20 | 0.34 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.34 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 9/20 | 0.34 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4170614 | 0.88 | KDR (0.43) | KDRKDM4EABCB1 | |
| SCHEMBL4178551 | 0.87 | KDR (0.36) | KDRKDM4CFLT1 | |
| SCHEMBL4181413 | 0.82 | QPCT (0.33) | KDR | |
| SCHEMBL4174895 | 0.82 | KDR (0.48) | KDRFLT1 | |
| SCHEMBL4181723 | 0.80 | CYP1A2 (0.42) | KDRKDM4EHTTSMN1; SMN2NPSR1 | |
| SCHEMBL4173399 | 0.80 | KDR (0.49) | KDRADRA2CKDM4EKDM6BKDM4A | |
| SCHEMBL4174196 | 0.79 | KDM4E (0.37) | KDRKDM4EKDM4C | |
| SCHEMBL4180846 | 0.76 | TUBB4A (0.43) | KDRKDM4E | |
| SCHEMBL4181336 | 0.76 | TUBB4A (0.40) | KDRADRA2CKDM4EHTTSMN1; SMN2 | |
| SCHEMBL4181696 | 0.75 | MEN1 (0.37) | KDM4EABCB1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | CHEN XIAOLING | 2009-12-24 | — | — | US | disclosed |
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | IMCLONE SYSTEMS INCORPORATED (US) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048301-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE AS ANTICANCER AGENTS | TP53, MCL1, VHL | KDR 3284/4885ADRA2C 3817/4885KDM4E 2144/4885 |
| US-20090318438-A1 | Heterocyclic compounds and their use as anticancer agents | TP53, MCL1, VHL | KDR 3284/4885ADRA2C 3817/4885KDM4E 2144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.